宫内暴露于生物反应调节剂儿童接种减毒活疫苗的安全性
该回顾性队列研究基于疫苗安全数据链,纳入2006–2017年孕妇及其子女,发现孕期使用生物反应调节剂(BRM)的比例从8/10,000升至46/10,000。宫内暴露BRM的儿童与未暴露儿童相比,临床结局比例相似,12月龄轮状病毒疫苗覆盖率略低(79.5% vs 85.4%),接种含麻疹或轮状病毒疫苗后的特别关注不良事件(AESI)罕见且比例相似。结论认为宫内暴露BRM未增加临床显著感染或减毒活疫苗接种后不良事件风险,可与其他儿童一样按程序接种。
要点
- 孕期BRM使用率从2006年8/10,000升至2017年46/10,000。
- 宫内暴露BRM儿童临床结局比例与未暴露儿童相似。
- 暴露儿童12月龄轮状病毒疫苗覆盖率略低(79.5% vs 85.4%)。
核心结论
- 宫内暴露于BRM未增加临床显著感染或减毒活疫苗接种后不良事件的风险。
- 宫内暴露BRM的儿童可按与其他儿童相同的程序接种减毒活疫苗。
研究设计与样本
- 回顾性队列研究,基于疫苗安全数据链,纳入2006–2017年孕妇及所生子女。
- 共纳入1,205,416名孕妇,其中2,243名使用BRM(19/10,000)。
主要发现
- 孕期BRM使用率从2006年8/10,000增至2017年46/10,000。
- 最常使用的BRM为依那西普(35.9%)、阿那白滞素(23.2%)、阿达木单抗(21.4%)和英夫利西单抗(19.9%)。
- 除肺炎外,暴露与未暴露儿童中关注的临床结局均罕见,且比例相似。
- 12月龄时暴露儿童轮状病毒疫苗覆盖率低于未暴露儿童(79.5% vs 85.4%)。
- 接种含麻疹或轮状病毒疫苗后的AESI罕见,且暴露与未暴露儿童比例相似。
临床怎么用
- 儿科医生可对宫内暴露BRM的儿童按常规程序接种减毒活疫苗。
- 无需因宫内BRM暴露而延迟或回避减毒活疫苗接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES:: To estimate the prevalence of biological response modifiers (BRM) use during pregnancy and compare clinical outcomes in infants, live-attenuated immunization coverage and adverse events of special interest (AESI) following immunization. METHODS:: We conducted a retrospective cohort study among pregnant people between 2006 – 2017 and children born from these pregnancies within the Vaccine Safety Datalink. We estimated the proportion of women who used BRM during pregnancy overall and by year of pregnancy onset. We compared clinical outcomes, live-attenuated vaccination coverage, and AESI occurring in specific risk intervals following immunization in children exposed and unexposed in utero to BRM. RESULTS:: Of the 1,205,416 pregnant people, 2,243 used BRM (19/10,000), which increased from 8/10,000 in 2006 to 46/10,000 pregnant people in 2017. The most frequently dispensed or prescribed BRM were etanercept (35.9%), anakinra (23.2%), adalimumab (21.4%) and infliximab (19.9%). Except for pneumonia, clinical outcomes of interest were rare among exposed and unexposed children to BRM. Proportions of clinical outcomes were similar between both groups. A lower proportion of children exposed to BRM receive rotavirus vaccines by age 12 months compared with unexposed children (79.5% vs. 85.4%). AESI with measles-containing vaccines or rotavirus vaccines were rare and proportions of these were similar among exposed and unexposed children. CONCLUSION:: In utero exposure to BRM was not associated with an increased risk of clinically significant infections or adverse events following live-attenuated vaccines. These data provide reassurance that children exposed in utero to BRM can receive live-attenuated vaccines on the same schedule as other children.
引用
- Zerbo O, Modaressi S, Goddard K, et al. Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero. Pediatrics. 2022. PMID: 35773517. doi:10.1542/peds.2021-056021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。